Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. reports developments in cloud software, data, AI, and consulting for the life sciences industry. Company news commonly covers adoption of the Veeva Vault Platform, including Development Cloud, Quality Cloud, Commercial Cloud, Data Cloud, Vault CRM, and Veeva MedTech applications for clinical, regulatory, quality, commercial, and medical operations.
Updates also include customer standardization projects with pharmaceutical, biotechnology, medical device, and diagnostics companies; product and data offerings such as Link Key People and Veeva AI; fiscal results and subscription revenue trends; and corporate actions such as acquisitions, including the completed purchase of Ostro as a life sciences brand engagement platform.
Veeva Systems (VEEV) will present at two investor conferences in September 2026. Paul Shawah, EVP Strategy, will speak at the Wells Fargo 21st Annual Healthcare Conference in Boston on Sept. 9, 2026, at 11:00 a.m. ET. CFO Brian Van Wagener will present at the Citi 2026 Global TMT Conference in New York on Sept. 10, 2026, at 10:50 a.m. ET. Both presentations will be webcast via Veeva's investor relations website.
Veeva Systems (NYSE: VEEV) announced Veeva Falcon Safety, an agentic safety operations product designed to streamline adverse event intake, case processing, and follow-up for biopharma companies. Falcon Safety will work with any E2B-compliant safety system, including Veeva Safety, Oracle Argus, and ArisGlobal LifeSphere MultiVigilance.
According to Veeva, Falcon Safety aims to help reduce costs, increase speed, and maintain compliance across all intake channels and safety systems. The product is part of Veeva AI, the company’s industry-specific AI solutions for life sciences, and is planned for early adopter availability in November 2026.
Veeva (NYSE: VEEV) reported fiscal 2027 Q2 total revenues of $928.0 million, up 18% year over year, with subscription revenues of $766.8 million, up 16%. GAAP operating income was $275.0 million (+40%), and GAAP net income was $273.4 million (+37%), or diluted EPS of $1.66.
Non-GAAP operating income reached $415.9 million (+18%), and non-GAAP net income was $387.4 million, or $2.35 per diluted share. Veeva highlighted strong adoption of Vault CRM, expansion of Veeva Falcon and Vault AI, and the acquisition of Copli. Cash from operations for the first six months was $1.37 billion.
For Q3 FY27, Veeva guided total revenues to $932–$935 million and non-GAAP EPS to $2.33–$2.34. For FY27, it forecast total revenues of $3.682–$3.687 billion and non-GAAP EPS of about $9.21.
Veeva Systems (NYSE: VEEV) announced that Biogen has committed to deploy Veeva Vault CRM globally as its commercial platform. Executives from both companies highlighted a shared focus on customer experience, innovation, and using advanced capabilities to support commercial strategies for complex therapies.
Vault CRM is part of the Vault CRM Suite, which includes the Agentic Call Report to generate Commercial Evidence and enable an AI‑driven, “agentic commercial” model aimed at getting appropriate medicines to more patients. Veeva also reiterates standard forward‑looking statement cautions and refers investors to its Form 10‑Q for the fiscal year ended April 30, 2026 for risk factors.
Veeva Systems (NYSE: VEEV) announced that Regeneron Pharmaceuticals has committed to deploy Veeva Vault CRM globally across its commercial organization. Regeneron plans to use the AI-powered platform to generate Commercial Evidence from field engagement, identify barriers to treatment adoption, and support faster, data-informed commercial decisions.
Vault CRM, part of the Vault CRM Suite, includes the Agentic Call Report, which turns each field interaction into structured insights while addressing prior issues with dropdown-based data and compliance concerns. The announcement extends the long-standing strategic partnership between Veeva and Regeneron.
Veeva Systems (NYSE: VEEV) announced on August 11, 2026 that Eli Lilly and Company has committed to deploy Veeva Vault CRM globally. Vault CRM is part of the Vault CRM Suite, which Veeva describes as the technology foundation for agentic commercial, a new AI-enabled commercial model to help bring the right medicines to more patients.
Executives from Lilly and Veeva highlighted the expansion of their strategic relationship as Lilly rolls out Vault CRM worldwide. Investors are directed to Veeva’s risk disclosures and forward-looking statement cautions in its Form 10-Q for the fiscal year ended April 30, 2026.
Veeva Systems (NYSE: VEEV) plans to announce financial results for its fiscal 2027 second quarter, ended July 31, 2026, after market close on Wednesday, August 26, 2026. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results, with prepared remarks posted to its investor relations site at 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available at ir.veeva.com following the live event.
Veeva Systems (NYSE: VEEV) announced Veeva EHS, a new environmental, health, and safety application within Veeva Quality Cloud. The solution aims to help manufacturing and testing sites identify, manage, and mitigate operational and environmental risks while supporting global compliance readiness.
Veeva EHS connects with Veeva QMS and Veeva Training so safety events can automatically trigger quality deviations and targeted retraining. The application is designed for real-time incident reporting, end-to-end investigation management, and transparency into leading indicators of risk. Early adopter availability is planned for August 2026.
Veeva Systems (NYSE: VEEV) acquired Copli, a pioneer in agentic medical, legal, and regulatory (MLR) solutions, and launched Veeva Falcon MLR.
The agentic MLR product aims to accelerate content review, with potential to eliminate 70% or more manual MLR labor within five years, supporting marketing teams, MLR groups, and agencies.
Veeva Systems (NYSE: VEEV) announced that biopharma company UCB is unifying its global pharmacovigilance operations on Veeva Safety Suite. UCB will standardize safety case intake, processing, submissions, content management, signal detection, and regulatory data sharing on a single platform to improve efficiency, automation, and global oversight.